Cellular Changes in Prostate Cancer Cells Induced by Intermittent Androgen Suppression
- 29 November 2006
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 52 (3) , 725-732
- https://doi.org/10.1016/j.eururo.2006.11.043
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- EAU Guidelines on Prostate CancerEuropean Urology, 2005
- Endocrine treatment of prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinomaCancer, 2002
- PSA decline is an independent prognostic marker in hormonally treated prostate cancer.European Urology, 1999
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993
- Carcinoma of the ProstateNew England Journal of Medicine, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989